Skip to main content
padlock icon - secure page this page is secure

Biomarkers of Aspirin Resistance

Buy Article:

$68.00 + tax (Refund Policy)

Aspirin therapy is the cornerstone of therapy and is considered as the “gold standard” antiplatelet agent for primary and secondary prevention of cardiovascular events. Aspirin inhibits the COX-1 enzyme and therefore blocks platelet thromboxane A2 synthesis. Several recent studies have suggested that some patients may not get the full benefits of aspirin therapy. These findings raise the question that some patients may be resistant to aspirin's antiplatelet effects. There is no universally accepted definition of aspirin resistance (AR). The exact mechanisms leading to AR are not very well understood but are likely multi-factorial. Several point-of-care assays of platelet function have been developed in recent years to rapidly screen individuals on aspirin as anti-platelet therapy. The ideal test would be capable of distinguishing individuals at risk of ischemic and bleeding events and could be used to guide dose adjustments in therapy. Utility of currently available tests in identifying aspirin-resistant patients remains to be determined. No data exist to guide aspirin therapy on the basis of platelet function test results. This article includes what AR means, the mechanisms, and clinical relevance of AR including platelet activity, methods to identify aspirin resistance, management of AR and relevant patents.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 11-dehydrothromboxane B2; Aggregometry; COX-1; CYP450 system; P-selectin; PlA polymorphism; UDP-glucuronosyl transferase; aspirin resistance; cyclooxygenase 1; mean platelet volume

Document Type: Research Article

Publication date: January 1, 2013

More about this publication?
  • Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more